Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 402-406

  Mendonza, Anisha E ^a   Gohh, Reginald Y ^b   Akhlaghi, Fatemeh ^a,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Concentration; LC MS MS; Mycophenolic acid; Saliva; Transferrin

Indexed keywords

ACETONITRILE; FORMIC ACID; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; METHANOL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN; TACROLIMUS;

ADULT; ANALYTIC METHOD; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SALIVA LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MALE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PRECIPITATION; QUANTITATIVE ANALYSIS; SUPERNATANT; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MASS SPECTROMETRY; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; REPRODUCIBILITY OF RESULTS; SALIVA; TACROLIMUS;

EID: 33748170158     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211826.65607.05     Document Type: Article

References (24)

1. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
2. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
3. Van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
4. Van GT, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005;80:S244-S253.
5. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
6. Langman LJ, LeGatt DF, Yatscoff W. Blood distribution of mycophenolic acid. Ther Drug Monit. 1994;16:602-607.
7. Weber LT, Shipkova M, Lamersdore T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol. 1998;9:1511-1520.
8. Dubrey SW, Holt DW, Banner N. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Ther Drug Monit. 1999;21:325-326.
9. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
10. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999;39:715-720.
11. Patel CG, Mendonza AE, Akhlaghi F, et al. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:287-294.
12. Streit F, Shipkova M, Armstrong VW, et al. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem. 2004;50:152-159.
13. Atcheson B, Taylor PJ, Mudge DW, et al. Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799:157-163.
14. Mendonza A, Gohh R, Akhlaghi F. Determination of cyclosporine in saliva using liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2004;26:569-575.
15. Jusko WJ, Milsap RL. Pharmacokinetic principles of drug distribution in saliva. Ann N Y Acad Sci. 1993;694:36-47.
16. Center for Drug Evaluation and Research: Food and Drug Administration. Bioanalytical method validation; guidance for industry 2001. http://www.fda.gov/cder/guidance/4252fnl.htm last accessed December 2005.
17. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49:1041-1044.
18. Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Ther Drug Monit. 2006;28:116-122.
19. Vining RF, McGinley RA. Hormones in saliva. Crit Rev Clin Lab Sci. 1986;23:95-146.
20. Svensson CK, Woodruff MN, Baxter JG, et al. Free drug concentration monitoring in clinical practice. Rationale and current status. Clin Pharmacokinet. 1986;11:450-469.
21. Hofman LF. Human saliva as a diagnostic specimen. J Nutr. 2001;131:1621S-1625S.
22. Haeckel R, Hanecke P. Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Eur J Clin Chem Clin Biochem. 1996;34:171-191.
23. O'Neil MJ, Smith A, Heckelman PE, et al. The Merck Index. 13th ed. Whitehouse Station, NJ: Merck Research Laboratories, Division of Merck and Co., Inc.; 2001.
24. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999;36:453-470.